Fig. 1

Scheme showing archetypal PDI and TXNDC5 domains and the role of TXNDC5 in diseases. Compared with the archetypal PDI domain (a), TXNDC5 has three a domains and no b domains (b); c: three TrX-like domains of TXNDC5 and their substrate binding sites; TXNDC5can be used as disease diagnostic biomarker (d) and treatment target (e). The surrounding text indicates the acting substrate or signal pathway. CC cervical cancer, ccRCC clear cell renal cell carcinoma, CRC colorectal cancer; CRPC castration-resistant prostate cancer, CTLC cutaneous T-cell lymphoma, GC gastric cancer, HCC hepatocellular carcinoma, HL hepatic Lipidosis, hMF human myocardial fibrosis, LC lung cancer, PF pulmonary fibrosis, LSCC laryngeal squamous cell carcinoma, PC pancreatic cancer, RA rheumatoid arthritis, RCC renal cell carcinoma, RF renal fibrosis, RRMM refractory/relapsed multiple myeloma;